Valuation: Evofem Biosciences, Inc.

Market Cap 861K 773K 715K 647K 1.21M 82.04M 1.22M 8.54M 3.4M 42.93M 3.23M 3.16M 136M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.28M 49.6M 45.85M 41.53M 77.58M 5.26B 78.52M 548M 218M 2.75B 207M 203M 8.75B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-4.41%
1 week+8.33%
Current month-12.16%
1 month-12.16%
3 months-14.13%
6 months-25.29%
Current year-31.58%
1 week 0.01
Extreme 0.0062
0.01
1 month 0.01
Extreme 0.006
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.01
3 years 0
Extreme 0.0008
0.23
5 years 0
Extreme 0.0008
1,320.19
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/12/24 A Sell

Chief Financial Officer

104 0.0010%
12/21/23 A Sell

Director

10 0.0001%
4/13/23 A Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-4.41%+8.33%-45.38%-91.86% 901K
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average -0.30%+2.14%+32.04%+59.58% 402.75B
Weighted average by Cap. +0.25%+1.55%+44.50%+89.02%

Financials

2024 2025
Net sales 19.36M 17.37M 16.06M 14.55M 27.18M 1.84B 27.51M 192M 76.49M 965M 72.66M 71.13M 3.06B 20.18M 18.11M 16.74M 15.16M 28.33M 1.92B 28.67M 200M 79.73M 1.01B 75.74M 74.14M 3.19B
Net income -8.86M -7.95M -7.35M -6.66M -12.44M -844M -12.59M -87.87M -35M -442M -33.25M -32.55M -1.4B 391K 351K 324K 294K 549K 37.24M 555K 3.88M 1.54M 19.49M 1.47M 1.44M 61.86M
Net Debt 45.84M 41.13M 38.02M 34.44M 64.34M 4.37B 65.12M 455M 181M 2.28B 172M 168M 7.25B 54.42M 48.82M 45.14M 40.88M 76.38M 5.18B 77.3M 540M 215M 2.71B 204M 200M 8.61B
Projected Income Statement - Annual - Evofem Biosciences, Inc.
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
28/10/26 $0.006500 -4.41% 86,401
27/10/26 $0.006800 +4.62% 10,025
26/10/26 $0.006500 -2.99% 9,742
23/10/26 $0.006700 +4.69% 319
22/10/26 $0.006400 +6.67% 11,148

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Evofem Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. EVFM Stock